| Name | Oxybutynin |
| Description | Oxybutynin (Ditropan) is a synthetic anticholinergic agent that is used for treatment of urinary incontinence and overactive bladder syndrome. |
| In vitro | In human liver microsomes, Oxybutynin inhibits CYP3A4- and CYP2D6-associated activities (testosterone 6β-hydroxylase and dextromethorphan O-demethylase, respectively).Oxybutynin (30,100 nM) competitively antagonizes acetylcholine-induced contraction. |
| In vivo | In human liver microsomes, Oxybutynin inhibits CYP3A4- and CYP2D6-associated activities (testosterone 6β-hydroxylase and dextromethorphan O-demethylase, respectively).Oxybutynin (30,100 nM) competitively antagonizes acetylcholine-induced contraction. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 66 mg/mL (184.62 mM), Sonication is recommended. DMSO : 45 mg/mL (125.88 mM), Sonication is recommended.
|
| Keywords | urinary urgency | urinary incontinence | urinary frequency | PotassiumChannel | Potassium Channel | Oxybutynin | OAB | Muscarinic acetylcholine receptor | mAChR | Kv channels | KcsA | Inhibitor | inhibit |
| Inhibitors Related | Adiphenine hydrochloride | Urethane | Hexamethonium Bromide | 1,8-Cineole | Tetraethylammonium bromide | Adenine | Ursodeoxycholic acid | Mitotane | Chenodeoxycholic acid | N,N-Dicyclohexylcarbodiimide | Arecoline | Chlorzoxazone |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |